Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Thymoma × Sunitinib × Clear all

Phase

Status

Completed 3 Unknown 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 14 Neoplasm Metastasis 6 Kidney Neoplasms 5 Breast Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Glioblastoma 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Neoplasms 2 Uveal Melanoma 1 Urethral Neoplasms 1 Thyroid Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Sarcoma 1 Recurrence 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Hormone Refractory Prostate Cancer 1 Glioma 1 Gastrointestinal Stromal Tumors 1 Gastrointestinal Neoplasms 1 Fatigue 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma 1 Carcinoid Tumor 1 Brain Neoplasms 1

Interventions

Radiotherapy 2 selinexor 1 pembrolizumab 1 isophosphamide mustard 1 epacadostat 1 envafolimab 1 Sunitinib 1 Ramucirumab 1 Radiation Dose Hypofractionation 1 Paclitaxel 1 Nivolumab 1 Leucovorin 1 Histocompatibility Testing 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Chemoradiotherapy 1 Carboplatin 1 68Ga-pentixafor 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03449173 2021-06-09

Style

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown

Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡